A recent trial showed that LOXO-101, a pan-TRK inhibitor also called larotrectinib, exhibited marked and durable efficacy against TRK fusion-positive cancers [10], which led to fast-tracked approval by the Food and Drug Administration. Here, TPM3 is linked to cancer.